Skip to main content
NCBI home page
PLOS One logoLink to PLOS One
. 2022 Feb 25;17(2):e0264504. doi: 10.1371/journal.pone.0264504

Comparison of mean platelet volume (MPV) and red blood cell distribution width (RDW) between psoriasis patients and controls: A systematic review and meta-analysis

Ping Yi 1,2,#, Jiao Jiang 1,2,#, Zheyu Wang 3,#, Xing Wang 4, Mingming Zhao 1,2, Haijing Wu 1,2,*, Yan Ding 5,*
Editor: Muhammad Tarek Abdel Ghafar6
PMCID: PMC8880915  PMID: 35213665

Abstract

Background

The predictive role of hematological indexes of mean platelet volume (MPV) and red cell distribution width (RDW) has been demonstrated in cardiovascular disease concomitant with psoriasis. This meta-analysis is intended to assess whether MPV and RDW can also serve as biomarkers for the early diagnosis and disease severity assessment of psoriasis.

Material and methods

13 studies which enrolled 1331 psoriasis patients and 919 healthy volunteers were included after screening the search results from PubMed, Embase and the Cochrane Library since inception to Mar 14, 2020. MPV of psoriasis participants and their counterparts was assessed in 10 studies, and RDW was evaluated in 4 studies, while the disease severity was measured by the Psoriasis Area and Severity Index (PASI) in 11 studies. Random-effect model analysis was applied to calculate pooled standard mean difference (SMD) with 95% confidence interval (95% CI).

Results

Associations of MPV and RDW with the presence of psoriasis were demonstrated (MPV: SMD = 0.503, 95% CI: 0.242–0.765; RDW: SMD = 0.522, 95% CI: 0.228–0.817), but no statistically significant correlation of MPV and disease severity of psoriasis was found in meta-regression analysis (p = 0.208). Subgroup analysis revealed that the diagnosis value of MPV and RDW was consistent regardless of PASI and study type. Heterogeneity analysis between studies was implemented by chi-squared test and I2 statistics. Begg’s and Egger’s test were utilized for the evaluation of publication bias. The sensitivity analysis revealed no significant alteration no matter which study was excluded.

Conclusion

MPV and RDW could serve as promising predictive diagnostic biomarkers of psoriasis.

Introduction

Psoriasis, a common chronic and systemic autoimmune inflammatory disease, is manifested with high individual heterogeneity symptoms, including recurrent scaly and burning skin patches, thick and dented nails, as well as swollen and stiff joints, complicated with a variety of other symptoms from cardiovascular, endocrine, digestive system and mental health [1]. The diagnosis of psoriasis primarily depends on three key items—the clinical characteristics of involving skin, nails and joints that are different from differential diagnosis; frequency of disease development; the skin biopsy [2]. Given the limitation of invasiveness and hysteresis in existing diagnostic methods [3], diagnostic biomarkers can benefit patients greatly. Up to now, promising biomarker profiles of candidate gene expression (IL36G, CCL27, NOS2, C10orf99, and S100A9) [4, 5], plasma proteins (desmoplakin, cytokeratin 17, polymeric immunoglobulin receptor, and complement C3, PI3, CCL22, IL-12B) [6, 7], inflammatory cytokines (adiponectin) [8], circulating microRNAs [9], GlycA [10] have been reported to assist the clinical diagnosis and reflect disease severity and inflammation state of psoriasis. However, examinations of these diagnostic biomarkers are time-consuming and costly compared with blood routine. Gaining more insight into the diagnostic information of hematological parameters is therefore considerable.

The hematological parameters used most frequently are red blood cell (RBC), hemoglobin (Hb), hematocrit (HCT), mean corpuscular volume (MCV), red cell distribution width (RDW), white blood cell (WBC), mean platelet volume (MPV), etc. To date, several studies have confirmed the role of some hematological parameters in certain diseases. As an example, the potential value of neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) has been verified in the clinical diagnosis of ankylosing spongdylitis (AS), Behçet’s disease, rheumatoid arthritis (RA) and psoriasis [11, 12]. Interestingly, MPV and RDW have been associated with the incident of primary adverse cardiac events in psoriasis vulgaris (PsV) and psoriatic arthritis (PsA) [13], and linked to inflammatory status and clinical progression in psoriasis patients. However, conflicting results have been described in an Egyptian case-control study that reported no significant difference in MPV value of psoriasis patients (n = 25) versus healthy controls (n = 25) [14]. To integrate these controversies, we screened all the published case-control studies, cohort studies and randomized control tests (RCTs) relating to this topic and conducted a meta-analysis, with the aim to uncover the association of MPV and RDW with diagnosis and disease severity of psoriasis.

Material and methods

Search strategy and literature screening

Two investigators searched and screened literature independently in the database of PubMed, Cochrane Library and Embase with cutoff date of Mar 14, 2020. This study was carried out following the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) statement with registration number of CRD42020178415 in the international prospective register of systematic reviews PROSPERO. Details of searching and screening were shown in S1 Table.

Inclusion and exclusion standard

The criteria of literature inclusion and exclusion were formulated and inspected by all authors and executed by two independent authors. A protocol agreement was reached by all authors. The inclusion and exclusion standards are listed as follows:

Inclusion standards

  1. case-control studies, cohort studies and RCTs measuring the value of MPV and/or RDW in psoriasis group with or without PsA and healthy control group;

  2. patients were not treated with systemic drugs or prescribed with any drugs affecting hematological indexes including antiplatelet drugs and nonsteroid anti-inflammatory drugs at least 2 weeks before the initiation of the project;

  3. published in English.

Exclusion standards

  1. the review, case report, conference abstract, letters, meta-analysis, sequencing data, bioinformatics analysis, and retracted articles;

  2. either the object of studies were not psoriasis patients or only male/female psoriasis patients;

  3. patients with cardiac diseases, hypertension, diabetes mellitus, obesity, dyslipidemia, pregnancy, hematological diseases and any other diseases interfering the hematological parameters;

  4. unavailable access and misleading data.

Data extraction and quality assessment

The data were extracted from 13 studies by two investigators independently, inclusive of first-author name, publication year, country, study type (prospective/retrospective study), sample size, gender, MPV, RDW, the Psoriasis Area and Severity Index (PASI) and hematology analyzer. SMDs and 95% CIs were calculated using random-effect model. The literature quality was assessed with Newcastle-Ottawa Scale (NOS), and NOS score of more than 6 indicates the adequate quality of the research.

Statistical analysis

Review Manager (RevMan 5.3) and Stata (Version 14.0) were used to analyze all extracted data. The associations of MPV and RDW with psoriasis were measured by pooling the SMD and 95% CI of each individual study. Heterogeneity analysis between studies was implemented by chi-squared test and I2 statistics. Random-effect model is suitable for the case of significant heterogeneity (I2>50%, p<0.05), unless this case, fixed-effect model is appropriate. Potential sources of heterogeneity should be interrogated by subgroup, sensitivity and meta-regression analysis in the condition of high heterogeneity. Begg’s and Egger’s test were used to detect publication bias.

Results

Included literature

The flowchart of screening and selecting process was shown in Fig 1. A total of 134 studies were identified initially and then 30 duplicated articles were removed. After reviewing the article title and abstract, 84 researches were further excluded by following inclusion and exclusion criteria. Further assessment of full-text excluded seven of the remaining 20 studies, of which two studies were excluded as patients were concomitant with metabolic syndrome that could interfere hematological indexes. Finally, 13 qualified studies were included for meta-analysis.

Fig 1. Flowchart of literature screening in the meta-analysis.

Fig 1

Open in a new tab

Characteristics of the included studies

The major characteristics of 13 studies [14–26] enrolling 1331 psoriasis patients and 919 healthy controls were shown in Table 1. Twelve studies from Asia region, and one from Egypt, Africa were included. As to the type of study design, eleven studies were prospective and two were retrospective. Nine studies reported MPV, three reported RDW and one reported both. Among them, one study by D.S. Kim, et al. [18] carried out two parallel case-control studies in psoriasis patients with high (PASI≥10, n = 52) or low PASI (PASI<10, n = 124) and healthy controls (n = 101). All included studies were scored more than 6 by NOS and defined as high quality (median,7.0 points; range, 6–8).

Table 1. General characteristic of the included studies.

First Author Year Country Study type NOS Psoriasis Control Hematology analyzer
N Gender(M/F) Age (Mean ± SD) MPV (Mean ± SD) RDW (Mean ± SD) PASI (Mean ± SD) N Gender(M/F) Age (Mean ± SD) MPV (Mean ± SD) RDW (Mean ± SD)
F. Canpolat 2010 Turkey P 7 106 59/47 41.4±14 8.7±1.1 NA 13.6±6.4 95 44/51 40.6±8 7.3±0.8 NA NA
H.M.A. Saleh 2013 Egypt P 7 25 13/12 31.56±10.09 9.16±1.28 NA 22.59±18.07 25 12/13 26.52±8.73 9.96±1.85 NA Coulter LH 750 Analyzer
S. Koça 2013 Turkey P 6 57 NA 41.8±10.8 8.56±0.90 NA 7.8±7.4 60 NA 40.0±9.4 8.19±0.74 NA NA
S. Koçb 2013 Turkey P 6 51 NA 42.1±11.1 NA 14.1±1.6 7.8±7.4 55 NA 40.1±13.1 NA 13.4±1 NA
Z. Ahmad 2014 Pakistan P 7 30 16/14 40.23±10.40 8.24±1.22 NA ≥10 30 17/13 35.20±9.73 7.29±0.77 NA Medonic-M seires Hematology Analyzer
D.S. Kima (1) 2015 Korea R 7 124 79/45 40±15.63 9.862±0.75 NA <10 101 42/59 37.02±15.44 9.724±0.59 NA Sysmex XE-2100
D.S. Kima (2) 2015 Korea R 7 52 36/16 39.40±14.12 10.08±0.67 NA ≥10 101 42/59 37.02±15.44 9.724±0.59 NA Sysmex XE-2100
D.S. Kimb 2015 Korea R 7 261 160/161 39.40±15.9 NA 13.6±3.5 NA 102 47/55 36.1±13.8 NA 12.9±0.7 Advia 2120 Hematology Analyzer
M. Unal 2016 Turkey P 6 320 154/166 37.34±13.45 8.248±1.15 NA NA 200 111/89 35.89±8.65 7.442 ±1.626 NA NA
V. Raghavan 2017 India P 8 50 38/12 46.10 ±11.99 9.65 ±2.07 15.16 ±3.88 15.88 ±2.51 50 41/7 50.62 ±14.78 8.51 ±1.64 13.66 ±1.21 Coulter LH780 Hematology Analyzer
Azza G.A. Farag 2018 Turkey P 7 70 40/30 41.47±8.16 9.65±1.12 NA 12.85± 4.97 60 40/20 40.0±10.30 8.92±0.78 NA Sysmex XN 1000 cell counter
Selma Korkmaz 2018 Turkey R 7 38 22/16 43±9.3 10.2 ±0.9 NA 2.78 ±2.05 35 18/17 42 ±10.4 10 ±1.7 NA Sysmex XE-2100
S.D. Pektas 2018 Turkey P 7 87 53/34 34.5±10.4 NA 13.625±0.837 10.2±3.7 76 42/34 32.7±9.7 NA 13.0±0.583 Advia 2120 Hematology Analyzer
G.O. Yavuz 2019 Turkey P 6 60 30/30 40.67±15.96 8.9±0.96 NA 8.1±5.2 30 15/15 41.67±11.68 8.8 ±0.89 NA NA
Open in a new tab

NOS: Newcastle–Ottawa quality assessment scale for case–control studies; MPV: mean platelet volume; RDW: red cell distribution width; PASI: Psoriasis Area and Severity Index; P: prospective study; R: retrospective study; NA: not available.

MPV and psoriasis

The forest plot for MPV of 932 psoriasis patients and 686 age-matched healthy controls in 10 studies was shown in Fig 2. All the participants were adults except for one study by M. Unal, et al. [24] that enrolled both adults and children. High variation of PASI values indicated high heterogeneity in disease severity of included patients. MPV values of psoriasis patients were elevated compared with healthy subjects in 9 studies, however, one study by H.M.A. Saleh [14] showed the opposite correlation of MPV and psoriasis with no statistical significance (P = 0.085). In this case, random-effect model analysis was used ascribing to substantial heterogeneity among studies (I2 = 84%, p = 0.000). Pooled SMDs revealed that MPV values were remarkably upregulated in psoriasis patients compared with healthy counterparts (SMD = 0.503, 95% CI: 0.242–0.765; p = 0.000).

Fig 2. Forest plot of MPV values and the presence of psoriasis.

Fig 2

Open in a new tab

The results of this analysis were credible because of the fixed pooled SMDs after removal of any individual study in sensitivity analysis, with the effect size ranging from 0.412 to 0.585 (Fig 3A). There was no significant publication bias manifested by Egger’s test (P = 0.511) (Fig 4A) and Begg’s test (P = 0.350) (Fig 4B).

Fig 3.

Fig 3

Open in a new tab

Sensitivity analysis of the association of MPV (A), RDW (B) and the presence of psoriasis.

Fig 4.

Fig 4

Open in a new tab

Publication bias of studies assessing MPV and RDW: Egger’s and Begg’s test of MPV (A and B) and RDW (C and D).

We applied subgroup analysis to investigate the potential variances affecting the pooled SMDs, containing PASI (PASI < 10 or PASI≥10, equal to mild psoriasis or moderate to severe psoriasis) and study type (retrospective or prospective study) (Figs 5 and 6, Table 2). SMD of MPV in patients with moderate to severe psoriasis (SMD = 0.659, 95% CI 0.199–1.118, p = 0.005; I2 = 87.4%, p = 0.283) was higher than that of patients with mild psoriasis (SMD = 0.236, 95% CI 0.059–0.414, p = 0.009; I2 = 0.0%, p = 0.605), while MPV was lower in retrospective studies (SMD = 0.315, 95% CI 0.054–0.576, p = 0.018; I2 = 42.1%, p = 0.178) compared with prospective ones (SMD = 0.573, 95% CI 0.237–0.909, p = 0.001; I2 = 86.0%, p = 0.000). However, the statistical differences were not identified in meta-regression analysis, with P value of 0.208 and 0.459, respectively.

Fig 5. Stratified analyses of disease severity assessed by PASI for the association between MPV and psoriasis.

Fig 5

Open in a new tab

Fig 6. Stratified analyses of study type for the association between MPV and psoriasis.

Fig 6

Open in a new tab

Table 2. Subgroup analysis of MPV in psoriasis.

Stratification group N SMD (95%CI) Heterogeneity test
P I2(%)
Total 11 0.503(0.242,0.765) 0 84%
PASI
< 10 4 0.236(0.059,0.414) 0.605 0
≥10 6 0.659(0.199,1.118) 0.283 87.4
study type
prospective study 8 0.573(0.237,0.909) 0 86
retrospective study 3 0.315(0.054,0.576) 0.178 42.1
Open in a new tab

RDW and psoriasis

The forest plot for RDW of 449 psoriasis patients and 283 age-matched healthy controls in four studies was shown in Fig 7. RDW values in psoriasis patients were uncovered higher than healthy matching in four studies, and pooled SMDs also showed elevated RDW values in psoriasis patients (SMD = 0.522, 95% CI: 0.228–0.817, p = 0.001). Likewise, random-effect model analysis was applied due to substantial heterogeneity (I2 = 69.3%, p = 0.021).

Fig 7. Forest plot of RDW values and the presence of psoriasis.

Fig 7

Open in a new tab

The pooled SMDs were fixed in sensitivity analysis, with the effect size ranging from 0.371 to 0.662, confirming the consistency of the results of this analysis (Fig 3B). No significant publication bias was evidenced by Egger’s test (P = 0.367) (Fig 4C), as well as Begg’s test (P = 1.000) (Fig 4D).

Discussion

MPV refers to the average size of circulatory platelets derived from megakaryocytes in bone marrow, functioning as the key mediators of hemostasis and thrombosis, and thus a sensitive indicator of platelet activation or reactivity [27]. Nowadays, accumulating evidence has revealed the crucial role of platelets in immune-related and inflammatory diseases [28]. Mechanically, they store multiple immune-related chemokines, cytokines, and adhesion receptors in granules and synthesize thromboxane A2, interleukin (IL)-1, and platelet-activating factor (PAF) [28]. Once activated, platelets can express or upregulate P-selectin, CD40 ligand, Toll-like receptors, and integrins on their surface and release soluble agents such as chemokines, cytokines, 5-hydroxytryptamine (5-HT) and antimicrobial peptides to interact with immune cells [28]. Psoriasis is a chronic inflammatory Th17-driven skin disease with hyperkeratosis, dilated dermal blood vessels as well as infiltration of T cells and neutrophils [29]. Interestingly, platelet activation was found in the skin lesions of psoriasis instead of normal skin tissues and correlated with the disease severity [30].

To date, platelets were found largely involved in the pathogenesis of psoriasis. Firstly, enhanced polymorphonuclear neutrophils (PMNs) infiltrations in the psoriatic lesion and blood were in relation to the platelet surface antigens as well as the recruitment and inflammatory response caused by the soluble mediators [31]. Treatment depleting circulating platelets in imiquimod (IMQ)-induced psoriasis-like mouse model could significantly ameliorate disease severity and reduce the PMNs or platelet infiltration [31]. Moreover, many chemokines, cytokines and specific markers released or upregulated by platelets might trigger immune process. P-selectin was highly expressed on the surface of platelet in psoriasis, and could increase the aggregation of platelets and leukocytes as well as leukocyte rolling in murine skin [32]. Platelet factor 4 (PF4) and β-thromboglobulin (β-TG), the most abundant CXC chemokines of platelet α-granules, were found increased in human psoriasis and associated with PASI scores [33]. They were related to the adhesion and migration of neutrophil granulocytes and monocytes [34]. Besides, PF4 could increase IL‐17 producing cells in CD4+ T cells [35]. 5-HT was another molecule expressed in psoriatic lesions, leading to the immune infiltration by increasing vascular permeability, and inhibition therapy of 5-HT was effective in patients with psoriasis [36–38]. The cytokine IL-1β was also involved in the skin inflammation of psoriasis via IL-1β-IL-1R Signaling Pathway [39].

Despite the close relation between platelets and psoriasis, controversies on diagnostic value of MPV in current studies are unignorable. For instance, opposite correlation between MPV and the presence of psoriasis has been identified in an Egyptian study by H.M.A. Saleh, et al. [14], while others indicated a positive association. A meta-analysis is therefore indispensable to address this controversy. In general, our meta-analysis has verified the positive correlation by pooling results from all included studies. Meanwhile, the meta-regression analysis of PASI showed the upward trend of MPV with disease severity, though the conclusion was not statistically significant. The moderate to severe psoriasis subgroup showed significant heterogeneity due to a large span of PASI of different participants with high clinical heterogeneity. Overall, our findings integrated scattered studies and further revealed the association of MPV and the presence of psoriasis rather than disease severity. Interestingly, one published meta-analysis assessing the MPV value and Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) score of SLE patients observed no relationship between MPV and disease activity of SLE, although the platelet activation plays a certain role in the pathogenesis of SLE [40].

Notably, it has been reported that MPV decreased with the variation degree associated with PASI after two-year systematic treatment in a small-sample retrospective study (n = 12) [17], but increased after 12-month infliximab or adalimumab treatment in a Japanese retrospective study enrolling patients with PsV (n = 186) and PsA (n = 50) [41]. The change of MPV value before and after treatment involves with a large spectrum of factors such as therapy type and duration, treatment respond and inflammation status of individuals, and more related clinical prospective researches are needed to reveal the correlation of MPV value in pre-/post-treatment and disease status.

RDW measures the variation of volume and size of RBCs that take part in inflammatory processes and coagulation. Inflammation disturbs erythroid maturation via membrane-bound β-receptor glycoprotein 130 (gp130) to elevate the value of RDW [42]. Inflammation-induced hydroxyl radicals and cytokines influence erythropoiesis [43]. It was reported to be positively associated with serum inflammatory indexs—high-sensitivity C-reactive protein (hsCRP) and erythrocyte sedimentation rate (ESR) in many diseases [44]. Higher RDW was found in patients with Alzheimer’s disease (AD), and it was considered as a marker of inflammation, AD presence and AD severity reflected by cognition status [45]. RDW also serves as a biomarker of cardiovascular disease susceptibility and inflammation levels in RA and AS [46]. The positive correlation of RDW with pro-inflammatory cytokines TNF-α and IL-6, as well as the negative association with anti-inflammatory cytokine IL-10 have proven the function as an auxiliary inflammatory biomarker in RA [47]. Upregulated inflammatory cytokines in the skin and peripheral blood of psoriasis patients, such as interferons, TNF-a, IL-1, IL-6 and IL-10, had an effect on erythropoiesis, leading to the enhanced RDW [48]. Thus, it is generally accepted that RDW is a potential inflammatory biomarker for psoriasis, but the specific roles of RBCs in psoriasis remain unclear. One large-scale retrospective study argued that RDW was higher in psoriasis patients with no significant association with PASI and CRP [49]. Three-month standard treatment caused a temporary reduction of RDW value in moderate to severe psoriasis patients [50], suggesting the predictive role of RDW in short-term treatment respond, however, more hematological parameters like NLR and PLR should be integrated into consideration in the long-term observation [41].

Although this meta-analysis has interrogated the significant relationship between two hematological parameters and psoriasis, there are some inevitable limitations. Firstly, hematology analyzer and reference range of MPV and RDW were not uniform between studies, which led to bias from inevitable inaccuracy of measurement. Secondly, standard treatment of psoriasis other than medicine affecting platelet function would influence the value of MPV and RDW, which might interfere the analysis results. Thirdly, the results may not be applied for all races and regions because of the majority of included studies are from Asian countries including Turkey, Korea, Pakistan and India. Finally, the sample size of retrospective study accounts for a large proportion, which reduces the evidential effectiveness of the analysis, and it’s even possible that the included studies are not sufficient to detect if there is a difference, thus well-designed clinical prospective trials and large scale RCTs are urgently needed to give potent evidence of our results.

Conclusion

It has been demonstrated that the values of MPV and RDW bear closely on the presence of psoriasis, though no relationship was found to the disease severity. These two promising indicators may benefit patients by providing auxiliary information for clinicians in the early diagnosis of psoriasis. On this setting, the association merits further verification in future study.

Supporting information

S1 Checklist

(DOC)

Click here for additional data file. (57KB, doc)
S1 Table. Literature searching strategy.

(PDF)

Click here for additional data file. (135.9KB, pdf)

Acknowledgments

JJ, PY and ZYW conceived and designed the work. Material preparation, data collection and analysis were performed by PY, JJ, ZYW, XW, and MMZ. The first draft of the manuscript was written by PY, JJ and ZYW and all authors commented on previous versions of the manuscript. PY, HJW and YD revised the manuscript, and HJW and YD contributed to article drafting, critical revision and final approval of the version to be published. All authors read and approved the final manuscript.

Data Availability

All relevant data are within the paper and its Supporting Information files.

Funding Statement

This work was supported by the Hunan Talent Young Investigator (No. 2019RS2012), Hunan Outstanding Young Investigator (No. 2020JJ2055), National Natural Science Foundation of China (No. 81960565, No. 81560275), Hainan Province Clinical Medical Center, Innovation Research Team Project of Natural Science Foundation of Hainan Province (No. 2018CXTD350) and the Key R&D Projects in Hainan Province (No. ZDYF2020147).

References

  • 1.Armstrong AW, Read C. Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review. Jama. 2020;323(19):1945–60. Epub 2020/05/20. doi: 10.1001/jama.2020.4006 . [DOI] [PubMed] [Google Scholar]
  • 2.Greb JE, Goldminz AM, Elder JT, Lebwohl MG, Gladman DD, Wu JJ, et al. Psoriasis. Nature reviews Disease primers. 2016;2:16082. Epub 2016/11/25. doi: 10.1038/nrdp.2016.82 . [DOI] [PubMed] [Google Scholar]
  • 3.Yadav K, Singh D, Singh MR. Protein biomarker for psoriasis: A systematic review on their role in the pathomechanism, diagnosis, potential targets and treatment of psoriasis. International journal of biological macromolecules. 2018;118(Pt B):1796–810. Epub 2018/07/19. doi: 10.1016/j.ijbiomac.2018.07.021 . [DOI] [PubMed] [Google Scholar]
  • 4.Reimann E, Lättekivi F, Keermann M, Abram K, Kõks S, Kingo K, et al. Multicomponent Biomarker Approach Improves the Accuracy of Diagnostic Biomarkers for Psoriasis Vulgaris. Acta dermato-venereologica. 2019;99(13):1258–65. Epub 2019/10/16. doi: 10.2340/00015555-3337 . [DOI] [PubMed] [Google Scholar]
  • 5.Wang X, Liu X, Liu N, Chen H. Prediction of crucial epigenetically‑associated, differentially expressed genes by integrated bioinformatics analysis and the identification of S100A9 as a novel biomarker in psoriasis. International journal of molecular medicine. 2020;45(1):93–102. Epub 2019/11/21. doi: 10.3892/ijmm.2019.4392 ; PubMed Central PMCID: PMC6889933. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Xu M, Deng J, Xu K, Zhu T, Han L, Yan Y, et al. In-depth serum proteomics reveals biomarkers of psoriasis severity and response to traditional Chinese medicine. Theranostics. 2019;9(9):2475–88. Epub 2019/05/28. doi: 10.7150/thno.31144 ; PubMed Central PMCID: PMC6526001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Reindl J, Pesek J, Krüger T, Wendler S, Nemitz S, Muckova P, et al. Proteomic biomarkers for psoriasis and psoriasis arthritis. Journal of proteomics. 2016;140:55–61. Epub 2016/04/12. doi: 10.1016/j.jprot.2016.03.040 . [DOI] [PubMed] [Google Scholar]
  • 8.Cataldi C, Mari NL, Lozovoy MAB, Martins LMM, Reiche EMV, Maes M, et al. Proinflammatory and anti-inflammatory cytokine profiles in psoriasis: use as laboratory biomarkers and disease predictors. Inflammation research: official journal of the European Histamine Research Society [et al. ]. 2019;68(7):557–67. Epub 2019/05/08. doi: 10.1007/s00011-019-01238-8 . [DOI] [PubMed] [Google Scholar]
  • 9.Liu Q, Wu DH, Han L, Deng JW, Zhou L, He R, et al. Roles of microRNAs in psoriasis: Immunological functions and potential biomarkers. Experimental dermatology. 2017;26(4):359–67. Epub 2016/10/27. doi: 10.1111/exd.13249 ; PubMed Central PMCID: PMC5837862. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Joshi AA, Lerman JB, Aberra TM, Afshar M, Teague HL, Rodante JA, et al. GlycA Is a Novel Biomarker of Inflammation and Subclinical Cardiovascular Disease in Psoriasis. Circulation research. 2016;119(11):1242–53. Epub 2016/09/23. doi: 10.1161/CIRCRESAHA.116.309637 ; PubMed Central PMCID: PMC5215065. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Hao X, Li D, Wu D, Zhang N. The Relationship between Hematological Indices and Autoimmune Rheumatic Diseases (ARDs), a Meta-Analysis. Scientific reports. 2017;7(1):10833. Epub 2017/09/09. doi: 10.1038/s41598-017-11398-4 ; PubMed Central PMCID: PMC5589752. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Paliogiannis P, Satta R, Deligia G, Farina G, Bassu S, Mangoni AA, et al. Associations between the neutrophil-to-lymphocyte and the platelet-to-lymphocyte ratios and the presence and severity of psoriasis: a systematic review and meta-analysis. Clinical and experimental medicine. 2019;19(1):37–45. Epub 2018/11/28. doi: 10.1007/s10238-018-0538-x . [DOI] [PubMed] [Google Scholar]
  • 13.Conic RR, Damiani G, Schrom KP, Ramser AE, Zheng C, Xu R, et al. Psoriasis and Psoriatic Arthritis Cardiovascular Disease Endotypes Identified by Red Blood Cell Distribution Width and Mean Platelet Volume. Journal of clinical medicine. 2020;9(1). Epub 2020/01/16. doi: 10.3390/jcm9010186 ; PubMed Central PMCID: PMC7019311. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Saleh H.M.A., EASA A.M. Onsy, Saad A.A. and Abd Ellah M.M.M. Platelet activation: a link between psoriasis per se and subclinical atherosclerosis–a case–control study. 2013. British Journal of Dermatology. 2013;169: pp 68–75. Epub 2013/02/17. doi: 10.1111/bjd.12285 [DOI] [PubMed] [Google Scholar]
  • 15.Koc S.¸ MSK, Altekin R.E., Er A., Demir I., Alpsoy E. ASSESSMENT OF RED CELL DISTRIBUTION WIDTH (RDW) IN PATIENTS WITH PSORIASIS. 2013. Poster Presentations / International Journal of Cardiology. 2013:S185–186. doi: 10.1177/1076029611418964 [DOI] [PubMed] [Google Scholar]
  • 16.Faraga Azza G.A., AAZ, Habibc Mona S., Elnaidanyf Nada F., Ibrahemd Reda A.L., SSa, et al. Mean platelet volume: an immanent predictor of subclinical atherosclerosis in psoriatic patients compared with interleukin-1α and interleukin-6. Egyptian Women’s Dermatologic Society. 2018;15:80–87. doi: 10.1097/01.EWX.0000532719.31339.7c [DOI] [Google Scholar]
  • 17.Dae Suk Kim, JL, Kim Sung Hee, Kim Soo Min, and Lee Min-Geol. Mean Platelet Volume Is Elevated in Patients with Psoriasis Vulgaris. Yonsei Med J. 2015;56(3):712–718. doi: 10.3349/ymj.2015.56.3.712 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Das Suk KIM, DS, Hyunjoong JEE, Tae-Gyun KIM, Sung Hee KIM, Do Young KIM, et al. Red blood cell distribution width is increased in patients with psoriasis vulgaris: A retrospective study on 261 patients. Journal of Dermatology. 2015;42:1–5. doi: 10.1111/1346-8138.12865 [DOI] [PubMed] [Google Scholar]
  • 19.Eskioğlu FCHAF. Mean platelet volume in psoriasis and psoriatic arthritis. Clinical Rheumatology. 2010;29:325–328. doi: 10.1007/s10067-009-1323-8 [DOI] [PubMed] [Google Scholar]
  • 20.Göknur Özaydın Yavuz* İHY. Novel inflammatory markers in patients with psoriasis. Eastern Journal of Medicine. 2019;24(1): 63–68. doi: 10.5505/ejm.2019.19327 [DOI] [Google Scholar]
  • 21.Korkmaz S. Mean platelet volume and platelet distribution width levels in patients with mild psoriasis vulgaris with metabolic syndrome. Adv Dermatol Allergol. 2018: 367–371. doi: 10.5114/ada.2017.71285 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Koc S.¸ MSK, Altekin R.E., Demir I., Alpsoy E. MEAN PLATELET VOLUME IN PATIENTS WITH PSORIASIS WITHOUT RISK FACTORS FOR CARDIOVASCULAR DISEASE. Poster Presentations / International Journal of Cardiology. 2013:S182–3. doi: 10.1016/S0167-5273(13)70460-1. [DOI] [Google Scholar]
  • 23.Suzan Demir Pektas GP, Tosun Kursad, Dogan Gursoy, Neselioglu Salim, and Erel Ozcan. Evaluation of Erythroid Disturbance and Thiol-Disulphide Homeostasis in Patients with Psoriasis. BioMed Research International. 2018. doi: 10.1155/2018/9548252 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Unal M. Platelet mass index is increased in psoriasis. A possible link between psoriasis and atherosclerosis. Arch Med Sci Atheroscler Dis. 2016;1:e145–e149. doi: 10.5114/amsad.2016.64444 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Raghavan Vijayashree, RKNR, Rao Ramesh K, Kuberan Abinaya. A Correlative Study between Platelet Count, Mean Platelet Volume and Red Cell Distribution Width with the Disease Severity Index in Psoriasis Patients. Journal of Clinical and Diagnostic Research. 2017. Sep, Vol-11(9): EC13–EC16 doi: 10.7860/JCDR/2017/31172.10639 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Zaheer Ahmad SJA, Arif Maan Muhammad, Khalid Uzma, Hussain Abid. Comparison of mean platelet volume in patients with psoriasis and healthy individuals. Journal of Pakistan Association of Dermatologists. 2014;24 (1):1–3. [Google Scholar]
  • 27.Leader A, Pereg D, Lishner M. Are platelet volume indices of clinical use? A multidisciplinary review. Annals of medicine. 2012;44(8):805–16. Epub 2012/03/15. doi: 10.3109/07853890.2011.653391 . [DOI] [PubMed] [Google Scholar]
  • 28.Tamagawa-Mineoka R. Important roles of platelets as immune cells in the skin. Journal of dermatological science. 2015;77(2):93–101. Epub 2014/12/03. doi: 10.1016/j.jdermsci.2014.10.003 . [DOI] [PubMed] [Google Scholar]
  • 29.Eberle FC, Brück J, Holstein J, Hirahara K, Ghoreschi K. Recent advances in understanding psoriasis. F1000Research. 2016;5. Epub 2016/05/10. doi: 10.12688/f1000research.7927.1 ; PubMed Central PMCID: PMC4850872. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Garshick MS, Tawil M, Barrett TJ, Salud-Gnilo CM, Eppler M, Lee A, et al. Activated Platelets Induce Endothelial Cell Inflammatory Response in Psoriasis via COX-1. Arteriosclerosis, thrombosis, and vascular biology. 2020;40(5):1340–51. Epub 2020/03/07. doi: 10.1161/ATVBAHA.119.314008 ; PubMed Central PMCID: PMC7180109. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Herster F, Bittner Z, Codrea MC, Archer NK, Heister M, Löffler MW, et al. Platelets Aggregate With Neutrophils and Promote Skin Pathology in Psoriasis. Frontiers in immunology. 2019;10:1867. Epub 2019/09/03. doi: 10.3389/fimmu.2019.01867 ; PubMed Central PMCID: PMC6706802. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Ludwig RJ, Schultz JE, Boehncke WH, Podda M, Tandi C, Krombach F, et al. Activated, not resting, platelets increase leukocyte rolling in murine skin utilizing a distinct set of adhesion molecules. The Journal of investigative dermatology. 2004;122(3):830–6. Epub 2004/04/17. doi: 10.1111/j.0022-202X.2004.22318.x . [DOI] [PubMed] [Google Scholar]
  • 33.Tamagawa-Mineoka R, Katoh N, Ueda E, Masuda K, Kishimoto S. Elevated platelet activation in patients with atopic dermatitis and psoriasis: increased plasma levels of beta-thromboglobulin and platelet factor 4. Allergology international: official journal of the Japanese Society of Allergology. 2008;57(4):391–6. Epub 2008/09/18. doi: 10.2332/allergolint.O-08-537 . [DOI] [PubMed] [Google Scholar]
  • 34.Kim J, Krueger JG. Highly Effective New Treatments for Psoriasis Target the IL-23/Type 17 T Cell Autoimmune Axis. Annual review of medicine. 2017;68:255–69. Epub 2016/10/01. doi: 10.1146/annurev-med-042915-103905 . [DOI] [PubMed] [Google Scholar]
  • 35.Affandi AJ, Silva-Cardoso SC, Garcia S, Leijten EFA, van Kempen TS, Marut W, et al. CXCL4 is a novel inducer of human Th17 cells and correlates with IL-17 and IL-22 in psoriatic arthritis. European journal of immunology. 2018;48(3):522–31. Epub 2017/12/02. doi: 10.1002/eji.201747195 ; PubMed Central PMCID: PMC5888178. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Cloutier N, Paré A, Farndale RW, Schumacher HR, Nigrovic PA, Lacroix S, et al. Platelets can enhance vascular permeability. Blood. 2012;120(6):1334–43. Epub 2012/05/01. doi: 10.1182/blood-2012-02-413047 . [DOI] [PubMed] [Google Scholar]
  • 37.Thorslund K, Svensson T, Nordlind K, Ekbom A, Fored CM. Use of serotonin reuptake inhibitors in patients with psoriasis is associated with a decreased need for systemic psoriasis treatment: a population-based cohort study. Journal of internal medicine. 2013;274(3):281–7. Epub 2013/05/29. doi: 10.1111/joim.12093 . [DOI] [PubMed] [Google Scholar]
  • 38.Thorslund K, El-Nour H, Nordlind K. The serotonin transporter protein is expressed in psoriasis, where it may play a role in regulating apoptosis. Archives of dermatological research. 2009;301(6):449–57. Epub 2009/03/06. doi: 10.1007/s00403-009-0933-y . [DOI] [PubMed] [Google Scholar]
  • 39.Cai Y, Xue F, Quan C, Qu M, Liu N, Zhang Y, et al. A Critical Role of the IL-1β-IL-1R Signaling Pathway in Skin Inflammation and Psoriasis Pathogenesis. The Journal of investigative dermatology. 2019;139(1):146–56. Epub 2018/08/19. doi: 10.1016/j.jid.2018.07.025 ; PubMed Central PMCID: PMC6392027. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Zhao CN, Mao YM, Wang P, Guan SY, Sam NB, Li XM, et al. Lack of association between mean platelet volume and disease activity in systemic lupus erythematosus patients: a systematic review and meta-analysis. Rheumatology international. 2018;38(9):1635–41. Epub 2018/05/31. doi: 10.1007/s00296-018-4065-6 . [DOI] [PubMed] [Google Scholar]
  • 41.Asahina A, Kubo N, Umezawa Y, Honda H, Yanaba K, Nakagawa H. Neutrophil-lymphocyte ratio, platelet-lymphocyte ratio and mean platelet volume in Japanese patients with psoriasis and psoriatic arthritis: Response to therapy with biologics. The Journal of dermatology. 2017;44(10):1112–21. Epub 2017/05/12. doi: 10.1111/1346-8138.13875 . [DOI] [PubMed] [Google Scholar]
  • 42.Bester J, Pretorius E. Effects of IL-1β, IL-6 and IL-8 on erythrocytes, platelets and clot viscoelasticity. Scientific reports. 2016;6:32188. Epub 2016/08/27. doi: 10.1038/srep32188 ; PubMed Central PMCID: PMC4999875. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Pretorius E. The adaptability of red blood cells. Cardiovasc Diabetol. 2013;12:63. Epub 2013/04/13. doi: 10.1186/1475-2840-12-63 ; PubMed Central PMCID: PMC3637111. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Lippi G, Targher G, Montagnana M, Salvagno GL, Zoppini G, Guidi GC. Relation between red blood cell distribution width and inflammatory biomarkers in a large cohort of unselected outpatients. Arch Pathol Lab Med. 2009;133(4):628–32. Epub 2009/04/28. doi: 10.5858/133.4.628 . [DOI] [PubMed] [Google Scholar]
  • 45.Öztürk ZA, Ünal A, Yiğiter R, Yesil Y, Kuyumcu ME, Neyal M, et al. Is increased red cell distribution width (RDW) indicating the inflammation in Alzheimer’s disease (AD)? Arch Gerontol Geriatr. 2013;56(1):50–4. Epub 2012/10/30. doi: 10.1016/j.archger.2012.10.002 . [DOI] [PubMed] [Google Scholar]
  • 46.Doğan S, Atakan N. Red Blood Cell Distribution Width is a Reliable Marker of Inflammation in Plaque Psoriasis. Acta dermatovenerologica Croatica: ADC. 2017;25(1):26–31. Epub 2015/04/01. . [PubMed] [Google Scholar]
  • 47.He Y, Liu C, Zeng Z, Ye W, Lin J, Ou Q. Red blood cell distribution width: a potential laboratory parameter for monitoring inflammation in rheumatoid arthritis. Clin Rheumatol. 2018;37(1):161–7. Epub 2017/11/05. doi: 10.1007/s10067-017-3871-7 . [DOI] [PubMed] [Google Scholar]
  • 48.Weiss G, Goodnough LT. Anemia of chronic disease. The New England journal of medicine. 2005;352(10):1011–23. Epub 2005/03/11. doi: 10.1056/NEJMra041809 . [DOI] [PubMed] [Google Scholar]
  • 49.Paolo G, Davide G, Lippi G, Martina M, Giampiero G. Increased red blood cell distribution width in patients with plaque psoriasis. Journal of Medical Biochemistry. 2020:1–3. doi: 10.2478/jomb-2019-0003 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Balevi A, Olmuşçelik O, Ustuner P, Özdemir M. Is there any Correlation between Red Cell Distribution Width, Mean Platelet Volume Neutrophil Count, Lymphocyte Count, and Psoriasis Area Severity Index in Patients Under Treatment for Psoriasis? Acta dermatovenerologica Croatica: ADC. 2018;26(3):199–205. Epub 2018/11/06. . [PubMed] [Google Scholar]

Decision Letter 0

Jamie Males

5 Oct 2021

PONE-D-21-08384Comparison of mean platelet volume (MPV) and red blood cell distribution width (RDW) between psoriasis patients and controls: a systematic review and meta-analysisPLOS ONE

Dear Dr. Wang,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

The reviewers have identified several aspects of your study design that require further clarification, and have also pointed to a number of opportunities to improve the presentation of the manuscript. Please attend carefully to each of the points they have raised when preparing your revisions.

Please submit your revised manuscript by Nov 15 2021 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Jamie Males

Staff Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at 

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. We note that you have stated that you will provide repository information for your data at acceptance. Should your manuscript be accepted for publication, we will hold it until you provide the relevant accession numbers or DOIs necessary to access your data. If you wish to make changes to your Data Availability statement, please describe these changes in your cover letter and we will update your Data Availability statement to reflect the information you provide.

3. Please amend either the abstract on the online submission form (via Edit Submission) or the abstract in the manuscript so that they are identical.

4. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information. 

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: No

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: This is a meta-analysis of RDW and MPV as biomarkers and predictors of disease severity by Jiang et al.

1. Which drugs affecting hematologic diseases were excluded? Was biotin also excluded?

2. Was there a reason why male or female only studies were excluded? While there are potential gender differences in values, you could also run a subset analysis based on gender. Please include reasoning.

3. In limitations, this reviewer suggests adding that it's possible that even aggregated the included studies are not sufficient to detect if there is a difference.

Minor comments:

1. Suggest adding a transition sentence between promising biomarkers and hematologic parameters to improve flow

2. There are spelling/grammar/word errors throughout the paper and highlighting several here:

Introduction- change "The diagnose the psoriasis" to "The diagnosis of psoriasis"

Exclusion standards- change retreated to retracted

Results-11 and 12 should be spelled out

Figure 1- psoriasis is misspelled

Reviewer #2: The present meta-analysis aimed at investigating the association of MPV and RDW with diagnosis and disease severity of psoriasis by extracting data from thirteen studies appropriately chosen according to certain criteria.

The manuscript provides robust statistical analysis on the extracted data to assess the association of MPV and RDW with psoriasis, the heterogeneity among studies and the entity of the publication bias, as well as sensitivity and meta-regression analysis. Nevertheless, more details are needed to clarify the biological aspects related to MPV and RDW involvement in the pathogenesis of psoriasis.

• In the Discussion Section about MPV, authors mention findings from other studies that demonstrate elevation of this parameter in psoriasis patients, suggesting the involvement of increased platelet activation in the pathogenesis of psoriasis. Authors should give a deeper explanation on how MPV can be affected by the clinical-molecular alterations underlying the disease onset and progression, outlining possible mechanisms, pathways or molecular factors related (for instance, recent articles/reviews concerning the role of angiogenesis, cell proliferation, inflammation could be employed for a better introduction of the topic).

• Previous literature suggest RDW as a biomarker of cardiovascular disease susceptibility and inflammation levels in rheumatoid arthritis (RA) and ankylosing spongdylitis (AS). In the Discussion section, authors do not explore the connection between the variation of volume and size of red blood cells (measured by RDW) and the pathological processes underlying the development of psoriasis. Therefore, authors should explain how this parameter could be involved in the pathogenesis of the disease, justifying why clinicians should consider RDW informative in psoriasis patients especially regarding its predictive role in response to treatment.

• This meta-analysis demonstrates a correlation of MPV and RDW with the presence of psoriasis rather than with disease severity. Authors should implement the conclusion suggesting how this finding could help clinicians with the disease management, selection of therapies and patient follow-up, since they purpose these parameters as promising predictive and diagnostic biomarkers of psoriasis.

• References must have the same format even if they come from different databases to allow users easier searching on the source of information mentioned in the manuscript. Therefore, authors should review the bibliography inserting some missing information for example the Digital Object Identifier (doi) and the source of the cited article in all references.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2022 Feb 25;17(2):e0264504. doi: 10.1371/journal.pone.0264504.r002

Author response to Decision Letter 0

21 Oct 2021

Response to Reviewers

Thanks for your thoughtful and constructive comments. We have learned a lot from these comments, and addressed all of questions accordingly. Please find the revised texts highlighted in the revised manuscript, and the point-by-point responses as follows:

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at 

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

Response: We have checked the manuscript carefully and ensured that our manuscript meets PLOS ONE's style requirements, including file naming.

2. We note that you have stated that you will provide repository information for your data at acceptance. Should your manuscript be accepted for publication, we will hold it until you provide the relevant accession numbers or DOIs necessary to access your data. If you wish to make changes to your Data Availability statement, please describe these changes in your cover letter and we will update your Data Availability statement to reflect the information you provide.

Response: We have changed data availability statement to “all relevant data are within the manuscript and its Supporting Information files”, since there is no additional data for this manuscript.

3. Please amend either the abstract on the online submission form (via Edit Submission) or the abstract in the manuscript so that they are identical.

Response: We have ensured that abstract on the online submission and the abstract in the manuscript are identical.

4. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information. 

Response: We have included captions for our Supporting Information files at the end of our manuscript, and updated the in-text citation to match accordingly.

Reviewers' comments:

Reviewer #1: This is a meta-analysis of RDW and MPV as biomarkers and predictors of disease severity by Jiang et al.

1. Which drugs affecting hematologic diseases were excluded? Was biotin also excluded?

Response: Thanks for your comment. We have excluded the antiplatelet drugs and nonsteroid anti-inflammatory drugs but not biotin, because the measurement of MPV and RDW is independent of biotin in blood (certain laboratory results influenced by biotin include troponin, thyroid and other hormones and vitamin D level) (https://labtestsonline.org/articles/biotin-affects-some-blood-test-results).

2. Was there a reason why male or female only studies were excluded? While there are potential gender differences in values, you could also run a subset analysis based on gender. Please include reasoning.

Response: Thanks for your important comment. Indeed, only one monosexual study was excluded based on this criterion. The reason for establishing this standard is that all enrolled studies focused on both the male and female except one study by Ozlem Karabudak in 2008. As you mentioned, subset analysis could be used to diminish the effect of gender, however, only two included studies have provided the MPV value stratified by gender. Consequently, data is insufficient to get credible results for the subset analysis of gender. In order to avoid bias caused by gender, we have excluded this study by exclusive standard.

3. In limitations, this reviewer suggests adding that it's possible that even aggregated the included studies are not sufficient to detect if there is a difference.

Response: We have added “it's possible that even aggregated the included studies are not sufficient to detect if there is a difference” in limitations.

Minor comments:

1. Suggest adding a transition sentence between promising biomarkers and hematologic parameters to improve flow

Response: Thanks for your suggestion. We have added a transition sentence between promising biomarkers and hematologic parameters in introduction section to improve flow.

2. There are spelling/grammar/word errors throughout the paper and highlighting several here:

Introduction- change "The diagnose the psoriasis" to "The diagnosis of psoriasis"

Response: We have changed "The diagnose the psoriasis" to "The diagnosis of psoriasis"

in introduction section.

Exclusion standards- change retreated to retracted

Response: We have changed “retreated” to “retracted” in exclusion standards.

Results-11 and 12 should be spelled out

Response: We have spelled out 11 and 12 in results.

Figure 1- psoriasis is misspelled

Response: We have corrected the spelling mistake in figure 1.

Meanwhile, we have our manuscript polished by a native English speaker to make it more readable.

Reviewer #2: The present meta-analysis aimed at investigating the association of MPV and RDW with diagnosis and disease severity of psoriasis by extracting data from thirteen studies appropriately chosen according to certain criteria.

The manuscript provides robust statistical analysis on the extracted data to assess the association of MPV and RDW with psoriasis, the heterogeneity among studies and the entity of the publication bias, as well as sensitivity and meta-regression analysis. Nevertheless, more details are needed to clarify the biological aspects related to MPV and RDW involvement in the pathogenesis of psoriasis.

1. In the Discussion Section about MPV, authors mention findings from other studies that demonstrate elevation of this parameter in psoriasis patients, suggesting the involvement of increased platelet activation in the pathogenesis of psoriasis. Authors should give a deeper explanation on how MPV can be affected by the clinical-molecular alterations underlying the disease onset and progression, outlining possible mechanisms, pathways or molecular factors related (for instance, recent articles/reviews concerning the role of angiogenesis, cell proliferation, inflammation could be employed for a better introduction of the topic).

Response: Thanks for your constructive comment! We have cited more related literation to elaborate MPV-involved possible mechanisms underlying the disease onset and progression. Platelets synthesize, store, and secret inflammatory factors to induce inflammatory response. At the same time, they express P-selectin, CD40 ligand, Toll-like receptors, and integrins on their surface for the recruitment of polymorphonuclear neutrophils, cell adhesion and migration, as well as interaction with immune cells in the onset and progression of psoriasis.

2. Previous literature suggested RDW as a biomarker of cardiovascular disease susceptibility and inflammation levels in rheumatoid arthritis (RA) and ankylosing spongdylitis (AS). In the Discussion section, authors do not explore the connection between the variation of volume and size of red blood cells (measured by RDW) and the pathological processes underlying the development of psoriasis. Therefore, authors should explain how this parameter could be involved in the pathogenesis of the disease, justifying why clinicians should consider RDW informative in psoriasis patients especially regarding its predictive role in response to treatment.

Response: Thanks for your important comment. We pretty agree with your point of view. However, the erythroid disturbance in psoriasis patients has been hardly reported. A few studies reported that increased inflammatory cytokines in the skin and peripheral blood of psoriasis patients influenced erythropoiesis and elevated the value of RDW. We have cited and discussed these articles in the discussion section (page 17-18). Moreover, further studies are needed to have a more in-depth sight.

3. This meta-analysis demonstrates a correlation of MPV and RDW with the presence of psoriasis rather than with disease severity. Authors should implement the conclusion suggesting how this finding could help clinicians with the disease management, selection of therapies and patient follow-up, since they purpose these parameters as promising predictive and diagnostic biomarkers of psoriasis.

Response: Thanks for your comment. The current study could only demonstrate the correlation of MPV and RDW with the presence of psoriasis. Further analysis such as the disease severity and long-term prognosis is limited by unavailable data currently. Thus, we could only point out that MPV and RDW contribute to the early diagnosis of psoriasis for clinicians. As we know, patients could benefit a lot from early diagnosis and treatment. Besides, several studies have showed that the induction of these two indicators possibly provide reference significance for the judgement of treatment efficacy in the short term, however the comprehensive analysis of several hematological parameters are needed for efficacy evaluation in the long term. We have further elucidated the above opinion in the discussion section.

4. References must have the same format even if they come from different databases to allow users easier searching on the source of information mentioned in the manuscript. Therefore, authors should review the bibliography inserting some missing information for example the Digital Object Identifier (doi) and the source of the cited article in all references.

Response: We have reviewed the bibliography and inserted some missing information including doi and the source of the cited article in all references except for Ref. 26, 46 and 50 without available doi.

Attachment

Submitted filename: Response to Reviewers.docx

Click here for additional data file. (25.5KB, docx)

Decision Letter 1

Muhammad Tarek Abdel Ghafar

14 Feb 2022

Comparison of mean platelet volume (MPV) and red blood cell distribution width (RDW) between psoriasis patients and controls: a systematic review and meta-analysis

PONE-D-21-08384R1

Dear Dr. Wang,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Muhammad Tarek Abdel Ghafar, M.D

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #2: All comments have been addressed

Reviewer #3: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #2: Yes

Reviewer #3: Partly

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #2: Yes

Reviewer #3: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #2: Yes

Reviewer #3: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #2: Yes

Reviewer #3: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #2: The present version of the manuscript is considerably improved. In particular, the revised version of the manuscript provides a more detailed and clearer explanation of MPV and RDW involvement in the pathogenesis of psoriasis clarifying its related biological aspects.

Reviewer #3: The present meta-analysis aimed at investigating the association of MPV

and RDW with diagnosis and disease severity of psoriasis. The language of the manuscript is good and the structure is reasonable.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #2: No

Reviewer #3: No

Acceptance letter

Muhammad Tarek Abdel Ghafar

17 Feb 2022

PONE-D-21-08384R1

Comparison of mean platelet volume (MPV) and red blood cell distribution width (RDW) between psoriasis patients and controls: a systematic review and meta-analysis

Dear Dr. Wang:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Prof Muhammad Tarek Abdel Ghafar

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Checklist

    (DOC)

    Click here for additional data file. (57KB, doc)
    S1 Table. Literature searching strategy.

    (PDF)

    Click here for additional data file. (135.9KB, pdf)
    Attachment

    Submitted filename: Response to Reviewers.docx

    Click here for additional data file. (25.5KB, docx)

    Data Availability Statement

    All relevant data are within the paper and its Supporting Information files.

    Articles from PLoS ONE are provided here courtesy of PLOS

    RESOURCES